Singapore · Delayed Price · Currency is SGD Pharmesis International Company Description
Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People’s Republic of China.
The company operates through three segments: Western drugs/TCH Procurement, TCM formulated drugs/IP Rental, and Distribution.
It provides prescribed products and over-the-counter drugs. The company offers Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for rheumatoid arthritis and other rheumatic diseases treatment.
It also provides Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice and clear heat toxin; Shulinghou for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Fu Yang for the treatment skin pruritus and urticaria; and Xiong Dan Chuan Bei for the treatment of phlegm and cough.
Further, the company distributes chemical drugs, biological raw products, TCM products, antibiotics, and antibiotic agents.
The company provides western medicine products under the Kinna brand name; and TCM formulated products under the Longlife brand name.
Pharmesis International Ltd. was founded in 1996 and is based in Singapore.
| Country | Singapore |
| Founded | 1996 |
| Industry | Pharmaceutical Preparations |
| Employees | 1,096 |
| CEO | Xuedan Wu |
Contact Details
Address: 5 Kallang Sector Singapore, 349279 Singapore | |
| Phone | 65 6846 0766 |
| Website | pharmesis.com |
Stock Details
| Ticker Symbol | BFK |
| Exchange | Singapore Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Xuedan Wu | Chief Executive Officer |
| Chan Hoe Liang | Chief Financial Officer |